[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"attr-gene-mutation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:attr-gene-mutation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,79,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100518735","analysis-of-lumbar-spine-stenosis-specimens-for-identification-of-transthyretin-cardiac-amyloidosis-100518735",false,"NCT06034405","Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis","Inclusion Criteria:\n\n1. Clinically indicated spinal decompressive surgery within 20 years prior to enrollment.\n2. Age ≥50 years at the time of the surgery.\n3. Able to understand and sign the informed consent document after the nature of the study has been fully explained.\n\nExclusion Criteria:\n\nThe presence of any of the following excludes eligibility for enrollment in this study:\n\n1. Confirmed primary amyloidosis (AL) or secondary amyloidosis (AA).\n2. Known TTR amyloidosis.\n3. Other reason that would make the subject inappropriate for entry into this study.",true,"ALL","50 Years",{"count":19,"type":20},1663,"ESTIMATED","OBSERVATIONAL","Primary objective:\n\nTo identify older adults with transthyretin cardiac amyloidosis (ATTR-CA) early in the course of the illness, at a time when disease modifying therapies are most effective.\n\nThe specific aims of this epidemiologic investigation include:\n\n1. To identify subjects with previous lumbar spinal stenosis (LSS) Surgery who have evidence of transthyretin (TTR) amyloid deposits in spinal specimens and could be at risk for ATTR cardiac amyloidosis.\n2. To evaluate for ATTR-CA among those with localized TTR in the spinal tissue.\n\nThe study will also explore the following:\n\n1. The prevalence of amyloid in lumbar spinal stenosis specimens by Congo Red staining.\n2. The prevalence of TTR deposits among subjects with amyloid as determined by mass spectrometry.\n3. Evaluation of a novel artificial intelligence technique for that can identify amyloid histologically with standard H\\&E staining.\n4. Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in subject's spine by myocardial uptake of technetium pyrophosphate scan (Tc99-PYP).",[24,25,26,27,28,29],"Lumbar Spinal Stenosis","Cardiac Amyloidosis","ATTR Amyloidosis Wild Type","ATTR Gene Mutation","ATTRV122I Amyloidosis","Cardiomyopathy, Hypertrophic","RECRUITING","2026-06-02",{"date":33,"type":34},"2026-06-04","ACTUAL",{"date":36,"type":34},"2023-09-19",{"date":38,"type":20},"2028-05",{"name":40,"class":41},"Columbia University","OTHER",6,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":15,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100638540","petct-imaging-in-carriers-of-ttr-mutations-100638540","NCT07591038","PET\u002FCT Imaging in Carriers of TTR Mutations","Iodine-124 Evuzamitide PET\u002FCT Imaging in Carriers of TTR Mutations","EPIC-TTR","A. Pathogenic TTR Allele Carriers without HF\n\nInclusion:\n\n* men and women ages 30-80 who are pathogenic allele TTR carriers without history of HF (this will be assessed by study personnel and defined as : 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg\u002FmL or NT-proBNP ≥360 pg\u002FmL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician)\n* have already completed the protocol for NCT05489549 at UT Southwestern only\n\nExclusion:\n\n* a self-reported history or clinical history of HF\n* other known causes of cardiomyopathy\n* history of light-chain cardiac amyloidosis\n* prior type 1 myocardial infarction\n* cardiac transplantation\n* liver transplantation\n* body weight or habitus that exceeds the site-specific PET\u002FCT parameters\n* estimated glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2\n* inability to safely undergo PET\u002FCT\n* participating in a clinical trial for ATTR treatments or taking a fibril deleting agent\n* pregnancy or breastfeeding\n* patients taking heparin or heparin derivatives for anticoagulation\n* allergy to potassium iodide\n* known uncorrected thyroid disorder\n\nB. Subjects with symptomatic hATTR-CA (may be supplemented with other ATTR-CA genotypes including wild-type in the occasion of slow enrollment):\n\nInclusion:\n\n* men and women ages 30-80 who have symptomatic V122I hATTR-CA as determined by a history of HF (this will be assessed by study personnel and defined as : 1) history of hospitalization within the previous 12 months for management of HF; 2) an elevated B-type natriuretic peptide level ≥100 pg\u002FmL or NT-proBNP ≥360 pg\u002FmL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician)\n* hATTR-CA previously diagnosed histologically by amyloid staining and tissue typing with immunohistochemistry or mass spectrometry or by bone scintigraphy in without abnormal M-protein\n* TTR gene sequencing confirming the TTR variant\n* have already completed the protocol for NCT05489549 at UT Southwestern only\n\nExclusion:\n\n* other known causes of cardiomyopathy\n* history of light-chain cardiac amyloidosis\n* cardiac transplantation\n* liver transplantation\n* history of type I myocardial infarction\n* body weight or habitus that exceeds the site-specific PET\u002FCT parameters\n* estimated glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2\n* inability to safely undergo PET\u002FCT\n* participating in a clinical trial for ATTR treatments or taking a fibril deleting agent\n* patients taking heparin or heparin derivatives for anticoagulation\n* pregnancy or breastfeeding\n* allergy to potassium iodide\n* known uncorrected thyroid disorder\n\nC. Non-carrier race-matched controls:\n\nInclusion:\n\n* men and women ages 30-80 who are non-carriers without history of HF (this will be assessed by study personnel and defined as: 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg\u002FmL or NT-proBNP ≥360 pg\u002FmL within the previous 12 months; or 3) No clinical diagnosis of HF from a treating clinician\n* have previously enrolled in the Dallas Heart Study\n\nExclusion:\n\n* a self-reported history or clinical history of HF\n* other known causes of cardiomyopathy\n* history of light-chain cardiac amyloidosis\n* prior type 1 myocardial infarction\n* cardiac transplantation\n* liver transplantation\n* body weight or habitus that exceeds the site-specific PET\u002FCT parameters\n* estimated glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2\n* inability to safely undergo PET\u002FCT\n* participating in a clinical trial for ATTR treatments or taking a fibril deleting agent\n* patients taking heparin or heparin derivatives for anticoagulation\n* pregnancy or breastfeeding\n* allergy to potassium iodide\n* known uncorrected thyroid disorder","30 Years","80 Years",{"count":54,"type":20},80,"The purpose of this study is to determine if TTR gene carriers have early signs of a type of heart disease called amyloidosis using a new radiotracer dye (iodine-124 evuzamitide, I-124E).\n\nParticipants will undergo a screening that includes a medical history review and completion of quality-of-life surveys. Once screening is complete, participants will undergo an imaging test called a positron emission tomography (PET) scan combined with computed tomography (PET\u002FCT) to make images of the body. The new radiotracer dye (I-124E, a radioactive contrast) will be used during the PET\u002FCT to make amyloidosis visible in the heart and body.",[57,27,58,59],"ATTR","Cardiomyopathy","Transthyretin Mediated Amyloidosis (ATTR)",[61,62,63,64,65,66,57,67],"transthyretin","amyloidosis","carriers of abnormal gene","TTR","PET\u002FCT","evuzamitide","TTR gene","NOT_YET_RECRUITING","2026-05-15",{"date":71,"type":34},"2026-05-19",{"date":73,"type":20},"2026-08-01",{"date":75,"type":20},"2030-06-30",{"name":77,"class":41},"University of Texas Southwestern Medical Center",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100554436","eoss-attr-study-ehealth-based-operative-support-system-in-attr-cm-100554436","NCT06499064","EOSS-ATTR Study (eHealth Based Operative Support System in ATTR-CM)","Information and Communications Technology (ICT)-based Modeling of Transthyretin-associated Amyloidosis Cardiomyopathies (ATTR-CM) Care: EOSS-ATTR Study (eHealth Based Operative Support System in ATTR-CM)","eOSS-ATTR","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* HF diagnosis according to European Society of Cardiology (ESC)\n* Patients with a HF decompensation in the last 12 months\n* Confirmed diagnosis of ATTR-CM (ATTRv or ATTRwt)\n* Written informed consent\n\nExclusion Criteria:\n\n* Age\\\u003C18 years old\n* Participation in another clinical trial\n* Moderate or severe cognitive impairment without a competent caregiver\n* Lack of social support\n* Institutionalized patients\n* Life expectancy less than 1 year (excluding HF)\n* Institutional-based or end-of-life care\n* Serious psychiatric illness\n* Planned cardiac surgery\n* Planned heart transplantation or left ventricular assist device (LVAD) implant\n* Patients in haemodialysis program\n* The patient is unable or unwilling to give the informed consent to participate\n* The patient is considered an unsuitable candidate for this study according to the decision of the local investigator\n* Unstable patients with signs of fluid overload or low cardiac output","18 Years",{"count":89,"type":20},50,"INTERVENTIONAL",[92],"NA","Unicenter, proof-of-concept, prospective, randomised, controlled, open-label and blinded end-point adjudication trial to assess the effect on patient-reported outcomes measures (PROMs), patient-reported experience measures (PREMs) and clinical events of a mHealth-based comprehensive management program for patients with chronic heart failure (HF) due to transthyretin-associated amyloidosis (ATTR)-cardiomyopathy (CM) by means of remote daily telemonitoring of signs and symptoms and remote structured follow-up using videoconference.",[95,96,26,27],"Heart Failure","Amyloid Cardiomyopathy",[98],"eHealth; mHealth; telemonitoring; ATTR, heart failure","2024-10-21",{"date":101,"type":34},"2024-10-23",{"date":103,"type":20},"2024-12-01",{"date":105,"type":20},"2026-03-15",{"name":107,"class":41},"Hospital Universitari de Bellvitge",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":78},"100551306","attr-cardiac-amyloidosis-in-a-selected-population-100551306","NCT06458374","ATTR Cardiac Amyloidosis in a Selected Population","Prevalence and Long Tem Follow Up of ATTR Cardiac Amyloidosis in a Selected Population of Patients Operated on Carpal Tunnel Syndrome","Inclusion Criteria:\n\n* Male \\> 50 years\n* Female \\> 60 years\n* operated CTS at Ålesund Hospital\n\nExclusion Criteria:\n\n* not consented\n* do not speak Norwegian\n* secondary cause of CTS as traumatic or rheumatic\n* cannot be followed \\> 5 years due to other medical conditions\n* Cardiac disease at time of operation for CTS",{"count":116,"type":20},180,"Patients operated for carpal tunnel syndrome (CTS) at Ålesund Hospital (200 patients) will have a biopsy to diagnose ATTR amyloidosis. Patients with positive biopsy will be examined to decide wether they have cardiac amyloidosis. All patients with positive biopsy will be followed closely for 10 years wit echocardiography an clinically.",[26,27,119,25],"Carpal Tunnel Syndrome","2024-10-14",{"date":122,"type":34},"2024-10-16",{"date":124,"type":34},"2024-09-01",{"date":126,"type":20},"2039-02-28",{"name":128,"class":129},"Helse Møre og Romsdal HF","OTHER_GOV"]